Prior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or non-steroidal antiinflammatory drugs (NSAIDs)
Any NSAIDs or omega-3 free fatty acid supplementation within the last 14 days
The ability to interrupt non-steroidal anti-inflammatory drugs NSAIDS 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed
The ability to interrupt nonsteroidal antiinflammatory drug (NSAIDS) 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed
Nonsteroidal antiinflammatory drug (NSAIDs), IV contrast, aminoglycosides, or other potentially nephrotoxic drugs within 2 weeks of event 1
Ability to interrupt chronic non-steroidal anti-inflammatory drugs (NSAIDs) beginning 2 days before (5 days before for long-acting NSAIDs) and continuing for 2 days following administration of each pemetrexed dose
Planned ongoing treatment with other drugs thought to potentially have adverse interactions with either of the study drugs; if such drugs have been used, patients must have discontinued these agents at least 2 weeks (or as noted below) prior to initiating study treatment; examples include:\r\n* STRONG CYP3A4 inducers \r\n* Immunosuppressants (e.g., tacrolimus, leflunomide, tofacitinib, roflumilast, pimecrolimus)\r\n* NSAIDs\r\n** Note: NSAIDs must be discontinued within 5 days prior to initiating study treatment
Patients who have contraindications to the use of nonsteroidal antiinflammatory drug (NSAID’s) like chronic renal failure, coronary artery disease, or bleeding ulcers
Prior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or nonsteroidal anti-inflammatory drugs (NSAIDs)
Patients on nonsteroidal anti-inflammatory drugs (NSAIDs) will be eligible only when they are off NSAIDs for 14 days
Patients who are actively receiving steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) on a chronic basis and who are unwilling and/or unable to discontinue while on study therapy are NOT eligible for participation; NOTE: patients must have discontinued steroids or NSAIDs for 1 week prior to registration to be considered eligible for participation
Has prior allergic reaction or hypersensitivity to celecoxib, or nonsteroidal anti-inflammatory drugs (NSAIDs)
Patients with known hypersensitivity to celecoxib or other NSAIDs, aspirin or sulfonamides.
No prior allergic reaction or hypersensitivity to sulfonamides, celecoxib or NSAIDs
Prior allergic reaction or hypersensitivity to sulfonamides (may be allowed per investigator discretion based on patient history), celecoxib or NSAIDs
For pemetrexed arms: the ability to interrupt nonsteroidal anti-inflammatory drugs (NSAIDs) 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed
Hypersensitivity to cyclooxygenase-2 inhibitors, sulfonamides, NSAIDs, or salicylates; NSAID associated symptoms of gastritis.
Subject is receiving medication(s) that might affect immune function; use of H2 antagonists are prohibited as are all antihistamines five days before and five days after each injection of study vaccine; however, NSAIDS including COX-2 inhibitors, acetaminophen or aspirin are permitted
History of hypersensitivity or allergy to study drugs, aspirin, sulfonamides, or NSAIDs
Prior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or nonsteroidal anti-inflammatory drugs (NSAIDs)
Off study use of ketorolac or other NSAIDs prior to study administration
Known hypersensitivity to NSAIDs
Patients must not have received topical analgesics (e.g., capsaicin preparations) or any other analgesics (e.g., opiates, tramadol, with the exception of nonsteroidal anti-inflammatory drugs [NSAIDs], combination NSAIDs, and acetaminophen) within 14 days prior to registration
Patients must not have known hypersensitivity to eflornithine or sulindac or the excipients byproducts; patients must not have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other non-steroidal antiinflammatory drugs (NSAIDs)
Gastric intolerance attributable to ASA or NSAIDs
Use of ASA or NSAIDs for more than 5 days per month within 3 months of enrollment
Not willing or are unable to refrain from use of any non-study ASA, NSAIDs and leukotriene antagonists during the study period
Known intolerance to NSAIDs
History of hypersensitivity to COX-2 inhibitors, sulfonamides, nonsteroidal antiinflammatory drugs (NSAIDs), salicylates, or ursodeoxycholic acid
Gastric intolerance attributable to ASA or NSAIDs
Use of ASA or NSAIDs for more than 5 days per month within 3 months of enrollment
Not willing or are unable to refrain from use of any non-study ASA or NSAIDs during the study period
Known hypersensitivity to NSAIDs
Any NSAIDs or omega-3 free fatty acid supplementation within the last 14 days
No daily NSAIDs intake within the past 4 weeks; intermittent non-daily NSAIDs is allowed under principle investigator (PI) discretion
Participants with aspirin or other NSAIDs-induced asthma or hypersensitivity reaction, sulfonamide allergy
Known hypersensitivity to NSAIDs
Patients who have taken ASA or nonsteroidal anti-inflammatory drugs (NSAIDs) in the last two weeks or have an allergy to ASA will not be eligible for enrollment